Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on expe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Data Brief
Main Authors: Erpenbeck, Veit J., Popov, Todor A., Miller, David, Weinstein, Steven F., Spector, Sheldon, Magnusson, Baldur, Osuntokun, Wande, Goldsmith, Paul, Weiss, Markus, Beier, Jutta
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2016
Assuntos:
Data Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5021787/
https://ncbi.nlm.nih.gov/pubmed/27656673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2016.08.039
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares